What is it about?
Insulin-like growth factors (IGF) regulate growth and development and enhance cellular proliferation. IGF-binding protein-3 (IGFBP-3) inhibits IGF action by competitively binding IGFs that prevents their binding to the IGF cell surface receptor. Altered expression and serum levels of IGFBP-3 are associated with a number of malignancies. Study addressing the effect of IGFBP-3 gene polymorphism on bladder cancer is lacking. The aim of this study was to examine the effect of -202 A/C polymorphism of IGFBP-3 gene on development of bladder transitional cell carcinoma (TCC) and its correlation with serum concentration of IGF-1 and IGFBP-3 and with clinicopathological characteristics.
Photo by Amauri Acosta Montiel on Unsplash
Why is it important?
In the United States, bladder cancer is the fifth most common cancer in men, with an annual incidence of 18 cases per 10,000. Bladder cancer is 3 times more common in men than women. More than 90% of all bladder cancers are transitional cell carcinomas (TCC). The genetic polymorphisms in a number of genes have been shown as the modulators of bladder cancer risk. The insulin-like growth factor (IGF) system is extensively involved in human carcinogenesis. The IGF family is consisted of two peptide ligands (IGF-1 and IGF-2), two specific cell surface receptors (IGF-1R and IGF-2R), and six specific IGF-binding proteins (IGFBP-1 to IGFBP-6) (Sachdev and Yee 2007; Guvakova 2007). The mitogenic effects of IGF are mediated through interactions with IGF-1R and IGF-2R. The IGF-1R promotes motility and invasion of bladder cancer cells.
Read the Original
This page is a summary of: The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene, Archives of Toxicology, February 2011, Springer Science + Business Media, DOI: 10.1007/s00204-011-0671-8.
You can read the full text:
The following have contributed to this page